Impact of Vericiguat on Hemodynamics of Heart Failure
Status:
Not yet recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
Vericiguat is a new drug that was recently approved by the Food and Drug Administration for
patients with heart failure. In a large randomized controlled trial, this drug was found to
help patients with heart failure live longer and stay out of the hospital more than normal
treatment for heart failure. However, it is unclear how this drug positively impacts
"hemodynamics", meaning how the heart functions during activity/exercise, and how it may also
help blood pressure and health of the blood vessels and autonomic nervous system. This study,
funded by the drug manufacturer, Merck Corp, will enroll 30 patients with heart failure. The
patients will undergo baseline testing, and then be randomized to either receive vericiguat
or a placebo for about three months, and then come back for follow-up testing to learn more
about how the drug impacts heart function.